Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.（AXSM）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · AXSM · 截至 2026年6月8日
活动摘要
买入笔数
3
P-Purchase only
卖出笔数
37
近12个月
买卖比
0.08
Buy/Sell (by trades)
整体情绪
Axsome Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
AXSM 季度内部人买卖趋势
AXSM 内幕交易卖出 · AXSM 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · AXSM CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
AXSM 高管卖出股份 · AXSM 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 29, 2026 | Coleman Mark Director | Sale | 6,000 | $1.40M⚡ | Form 4 |
| Jun 1, 2026 | Coleman Mark Director | Sale | 6,000 | $1.38M⚡ | Form 4 |
| Jun 2, 2026 | Coleman Mark Director | Sale | 5,537 | $1.24M⚡ | Form 4 |
| May 4, 2026 | Jacobson Mark L. COO | Option | 4,517 | $58K | Form 4 |
| May 5, 2026 | Jacobson Mark L. COO | Option | 233 | $3K | Form 4 |
| May 5, 2026 | Jacobson Mark L. COO | Sale | 233 | $53K | Form 4 |
| May 4, 2026 | Jacobson Mark L. COO | Sale | 4,517 | $1.03M⚡ | Form 4 |
| Apr 22, 2026 | Maizel Ari Chief Commercial Officer | Option | 7,500 | $530K | Form 4 |
| Apr 22, 2026 | Maizel Ari Chief Commercial Officer | Sale | 7,500 | $1.37M⚡ | Form 4 |
| Feb 26, 2026 | Coleman Mark Director | Sale | 25,000 | $4.03M⚡ | Form 4 |
| Feb 26, 2026 | Jacobson Mark L. COO | Option | 35,378 | $101K | Form 4 |
| Feb 26, 2026 | Jacobson Mark L. COO | Sale | 35,378 | $5.73M⚡ | Form 4 |
| Feb 23, 2026 | Coleman Mark Director | Option | 6,250 | $31K | Form 4 |
| Feb 20, 2026 | Coleman Mark Director | Option | 12,485 | $62K | Form 4 |
| Feb 10, 2026 | Coleman Mark Director | Option | 5,193 | $42K | Form 4 |
| Feb 2, 2026 | TABUTEAU HERRIOT CEO · Director | Option | 32,410 | $260K | Form 4 |
| Feb 2, 2026 | TABUTEAU HERRIOT CEO · Director | Sale | 32,410 | $6.02M⚡ | Form 4 |
| Jan 22, 2026 | Pizzie Nick CFO | Option | 12,000 | $42K | Form 4 |
| Jan 22, 2026 | Pizzie Nick CFO | Sale | 12,000 | $2.26M⚡ | Form 4 |
| Jan 21, 2026 | Maizel Ari Chief Commercial Officer | Option | 7,500 | $530K | Form 4 |
| Jan 21, 2026 | Maizel Ari Chief Commercial Officer | Sale | 7,500 | $1.38M⚡ | Form 4 |
| Jan 5, 2026 | TABUTEAU HERRIOT CEO · Director | Option | 78,703 | $631K | Form 4 |
| Jan 7, 2026 | TABUTEAU HERRIOT CEO · Director | Option | 31,261 | $251K | Form 4 |
| Jan 6, 2026 | TABUTEAU HERRIOT CEO · Director | Option | 29,450 | $236K | Form 4 |
| Jan 5, 2026 | TABUTEAU HERRIOT CEO · Director | Sale | 78,703 | $13.48M⚡ | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 AXSM 内幕交易
AXSM 内幕交易
Axsome Therapeutics, Inc.（AXSM）内幕交易数据来源于公司内部人（包括TABUTEAU HERRIOT (CEO · Director), Jacobson Mark L. (COO), Coleman Mark (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。AXSM内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Axsome Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
AXSM 内幕交易 · 5个问题Axsome Therapeutics, Inc.（AXSM）的内部人包括高管和董事，如TABUTEAU HERRIOT (CEO · Director), Jacobson Mark L. (COO), Coleman Mark (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026